Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 20/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3386245 | 0.90 | HRH3 (0.56) | HRH3 | |
| SCHEMBL3921304 | 0.84 | PARP1 (0.36) | HRH3 | |
| SCHEMBL3930338 | 0.82 | HRH3 (0.54) | HRH3 | |
| SCHEMBL4421814 | 0.80 | KDR (0.39) | HRH3 | |
| SCHEMBL3385288 | 0.80 | HRH3 (0.40) | HRH3 | |
| SCHEMBL3384823 | 0.78 | HRH3 (0.44) | HRH3 | |
| SCHEMBL3385349 | 0.78 | HRH3 (0.44) | HRH3 | |
| SCHEMBL4563453 | 0.77 | KDR (0.39) | HRH3 | |
| SCHEMBL3387535 | 0.76 | HRH3 (0.40) | HRH3 | |
| SCHEMBL4421811 | 0.76 | HRH3 (0.43) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160089378-A1 | TREATMENT OF OSTEOARTHRITIS PAIN | ABBVIE INC (US) | 2016-03-31 | — | — | US | claimed |
| EP-2424528-A2 | TREATMENT OF OSTEOARTHRITIS PAIN | Abbott Laboratories (US) | 2012-03-07 | — | — | EP | claimed |
| WO-2010129242-A2 | TREATMENT OF OSTEOARTHRITIS PAIN | ABBOTT LABORATORIES (US) | 2010-11-11 | — | — | WO | claimed |
| US-20100273778-A1 | TREATMENT OF OSTEOARTHRITIS PAIN | ABBOTT LABORATORIES (US) | 2010-10-28 | — | — | US | claimed |
| US-20090221648-A1 | COMPOSITIONS FOR TREATMENT OF COGNITIVE DISORDERS | ABBOTT LABORATORIES (US) | 2009-09-03 | — | — | US | claimed |
| EP-1945639-A1 | TETRAHYDRONAPHTHYRIDINE DERIVATIVE | Pfizer Limited (GB) | 2008-07-23 | — | — | EP | claimed |
| US-20070179175-A1 | Tetrahydronaphthyridine Derivative | PFIZER LIMITED (GB) | 2007-08-02 | — | — | US | claimed |
| WO-2007052124-A1 | TETRAHYDRONAPHTHYRIDINE DERIVATIVE | PFIZER LIMITED (GB) | 2007-05-10 | — | — | WO | claimed |
| US-20160089378-A1 | TREATMENT OF OSTEOARTHRITIS PAIN | ABBVIE INC (US) | 2016-03-31 | — | — | US | disclosed |
| US-20160089378-A1 | TREATMENT OF OSTEOARTHRITIS PAIN | ABBVIE INC (US) | 2016-03-31 | — | — | US | disclosed |
| US-20160089378-A1 | TREATMENT OF OSTEOARTHRITIS PAIN | ABBVIE INC (US) | 2016-03-31 | — | — | US | disclosed |
| US-9186353-B2 | Treatment of osteoarthritis pain | ABBVIE INC. (US) | 2015-11-17 | — | — | US | disclosed |
| US-9186353-B2 | Treatment of osteoarthritis pain | ABBVIE INC. (US) | 2015-11-17 | — | — | US | disclosed |
| US-9186353-B2 | Treatment of osteoarthritis pain | ABBVIE INC. (US) | 2015-11-17 | — | — | US | disclosed |
| US-20070179175-A1 | Tetrahydronaphthyridine Derivative | PFIZER LIMITED (GB) | 2007-08-02 | — | — | US | disclosed |
| US-20070179175-A1 | Tetrahydronaphthyridine Derivative | PFIZER LIMITED (GB) | 2007-08-02 | — | — | US | disclosed |
| US-20070179175-A1 | Tetrahydronaphthyridine Derivative | PFIZER LIMITED (GB) | 2007-08-02 | — | — | US | disclosed |
| US-20070179175-A1 | Tetrahydronaphthyridine Derivative | PFIZER LIMITED (GB) | 2007-08-02 | — | — | US | disclosed |
| WO-2007052124-A1 | TETRAHYDRONAPHTHYRIDINE DERIVATIVE | PFIZER LIMITED (GB) | 2007-05-10 | — | — | WO | disclosed |
| WO-2007052124-A1 | TETRAHYDRONAPHTHYRIDINE DERIVATIVE | PFIZER LIMITED (GB) | 2007-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160089378-A1 | TREATMENT OF OSTEOARTHRITIS PAIN | HRH3, HRH4, HRH2 | HRH3 1/4885 |
| US-20100273778-A1 | TREATMENT OF OSTEOARTHRITIS PAIN | HRH3, HRH4, HRH2 | HRH3 1/4885 |
| US-20070179175-A1 | Tetrahydronaphthyridine Derivative | HRH4, HRH3, HRH1 | HRH3 2/4885 |
| US-20090221648-A1 | COMPOSITIONS FOR TREATMENT OF COGNITIVE DISORDERS | CHRNA4, CHRNA5, CHRNA3 | HRH3 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.